Pyrazine

Pyrazine

SCHEMBL1226089

c1cnccn1.c1cnccn1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
NAPRT Q6XQN6 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
LMNA P02545 2/20 0.42
MAPT P10636 2/20 0.42
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
HDAC8 Q9BY41 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP2D6 P10635 1/20 0.36
CHRM1 P11229 1/20 0.36
MAPK1 P28482 1/20 0.36
KCNA1 Q09470 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CTSD P07339 1/20 0.33
DDAH1 O94760 1/20 0.33
NOS1 P29475 1/20 0.33
NOTUM Q6P988 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrazine SCHEMBL5179 1.00
SCHEMBL31437084 1.00 TSHR (0.50) TSHRNAPRTTDP1LMNAMAPT
Pyrazine SCHEMBL4020461 0.93
Pyrazine SCHEMBL10496031 0.93
Pyrazine SCHEMBL5548201 0.93 TSHR (0.46) TSHRNAPRTTDP1LMNAMAPT
Pyrazine SCHEMBL940753 0.93
Pyrazine SCHEMBL8535297 0.93
Pyrazine SCHEMBL21647787 0.93
Pyrazine SCHEMBL21176400 0.93
Pyrazine SCHEMBL11336378 0.93

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718587-B2 Compound, epoxy curing catalyst and method for producing compound TOKYO OHKA KOGYO CO., LTD. (JP) 2023-08-08 US disclosed
EP-3683210-B1 COMPOUND, EPOXY CURING CATALYST AND METHOD FOR PRODUCING COMPOUND TOKYO OHKA KOGYO CO LTD (JP) 2022-08-24 EP disclosed
US-11142629-B2 Hydrogen barrier agent, hydrogen barrier film forming composition, hydrogen barrier film, method for producing hydrogen barrier film, and electronic element TOKYO OHKA KOGYO CO., LTD. (JP) 2021-10-12 US disclosed
US-20200283567-A1 COMPOUND, EPOXY CURING CATALYST AND METHOD FOR PRODUCING COMPOUND TOKYO OHKA KOGYO CO., LTD. (JP) 2020-09-10 US disclosed
EP-3683210-A1 COMPOUND, EPOXY CURING CATALYST AND METHOD FOR PRODUCING COMPOUND Tokyo Ohka Kogyo Co., Ltd. (JP) 2020-07-22 EP disclosed
US-20190300674-A1 HYDROGEN BARRIER AGENT, HYDROGEN BARRIER FILM FORMING COMPOSITION, HYDROGEN BARRIER FILM, METHOD FOR PRODUCING HYDROGEN BARRIER FILM, AND ELECTRONIC ELEMENT TOKYO OHKA KOGYO CO., LTD. (JP) 2019-10-03 US disclosed
US-20190302026-A1 Uniform, Functionalized, Cross-Linked Nanostructures for Monitoring pH WOOLEY KAREN L (US) 2019-10-03 US disclosed
CN-109863151-A Fused tricyclic pyridazinone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2019-06-07 CN disclosed
US-20180335385-A1 Uniform, Functionalized, Cross-Linked Nanostructures for Monitoring pH THE WASHINGTON UNIVERSITY 2018-11-22 US disclosed
CN-106415912-A Additive for electrochemical device, and electrolyte, electrode and electrochemical device comprising same 株式会社LG化学 2017-02-15 CN disclosed
US-4877883-A CATIONIC SURFACTANTS MEDICE CHEM.-PHARM. FABRIK PUTTER GMBH & CO. KG (DE) 1989-10-31 US disclosed
US-4874850-A CATIONIC TENSIDES IN MICELLES WITH HYDROPHOBIC PEPTIDES; DRUG DELIVERY MEDICE CHEM.-PHARM. FABRIK PUTTER GMBH & CO. (DE) 1989-10-17 US disclosed
US-4870174-A CATIONIC SURFACTANTS, SMALL CRITICAL MICELLE CONCENTRATIONS MEDICE CHEM.-PHARM. FABRIK (DE) 1989-09-26 US disclosed
EP-0277270-A2 N-alkylated quaternary nitrogen-containing heterocycles, process for their preparation and their use in pharmaceutical compositions MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) 1988-08-10 EP disclosed
EP-0262343-A2 N-alkylated quaternary nitrogen-containing heterocycles, process for their preparation and their use in pharmaceutical compositions MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) 1988-04-06 EP disclosed
EP-0262344-A2 N-alkylated quaternary nitrogen-containing heterocycles, process for their preparation and their use in pharmaceutical compositions MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) 1988-04-06 EP disclosed
EP-0260428-A2 Cationic surfactants and pharmaceutical compositions containing them MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) 1988-03-23 EP disclosed
EP-0260429-A2 N-alkylated quaternary nitrogen-containing heterocycles, process for their preparation and their use in pharmaceutical compositions MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) 1988-03-23 EP disclosed
EP-0258672-A2 Cationic surfactants and pharmaceutical compositions containing them MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) 1988-03-09 EP disclosed
EP-0257400-A2 Pharmaceutical compositions containing cationic surfactants MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) 1988-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200283567-A1 COMPOUND, EPOXY CURING CATALYST AND METHOD FOR PRODUCING COMPOUND MSMO1, RIOK1, ME1 TSHR 4428/4885NAPRT 1178/4885TDP1 4354/4885
US-20190302026-A1 Uniform, Functionalized, Cross-Linked Nanostructures for Monitoring pH MUC1, CD44, PFN1 TSHR 4673/4885NAPRT 3530/4885TDP1 1439/4885
US-11718587-B2 Compound, epoxy curing catalyst and method for producing compound MSMO1, RIOK1, ME1 TSHR 4428/4885NAPRT 1178/4885TDP1 4354/4885
US-20180335385-A1 Uniform, Functionalized, Cross-Linked Nanostructures for Monitoring pH MUC1, CD44, PFN1 TSHR 4673/4885NAPRT 3530/4885TDP1 1439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.